We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Efficacy of Pancrelipase on Postprandial Belching and Bloating.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00266721
Recruitment Status : Completed
First Posted : December 19, 2005
Last Update Posted : December 19, 2005
Information provided by:
Minneapolis Veterans Affairs Medical Center

December 15, 2005
December 19, 2005
December 19, 2005
January 2000
Not Provided
  • Abdominal bloating
  • Abdominal pain
  • Eructation
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
Efficacy of Pancrelipase on Postprandial Belching and Bloating.
Not Provided
The hypothesis of this study is that the administration of pancrelipase with meals will benefit symptoms of post-prandial bloating, pain and eructation.
Subjects will complete a double-blind crossover study in which, for one week periods, they will receive two pancrelipase tablets with each of the three major meals or a similarly administered identical placebo. Three times daily, subjects will rate the severity of belching, epigastric discomfort, epigastric fullness, bloating, and nausea.
Phase 3
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
  • Postprandial Bloating
  • Postprandial Belching
  • Postprandial Eructation
Drug: Pancrelipase (Creon) 2 tablets with each meal
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
October 2000
Not Provided

Inclusion Criteria:

  • Subjects will have either bothersome upper abdominal discomfort, bloating (feeling of abdominal distention) or belching following meals for at least 12 month's duration. Subjects must have had a normal upper gastrointestinal endoscopy and/or upper GI series during the preceding three years.

Exclusion Criteria:

  • Individuals with a history suggestive of organic disease such as recent weight loss, nausea, vomiting, GERD, recent changes in bowel habits will be excluded from the study.
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
Solvay Pharmaceuticals
Not Provided
Principal Investigator: Michael D Levitt, MD Minneapolis VAMC
Minneapolis Veterans Affairs Medical Center
December 2000

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP